Intercept Pharmaceuticals, Inc. (ICPT)
Market Cap | 794.36M |
Revenue (ttm) | 317.68M |
Net Income (ttm) | -61.61M |
Shares Out | 41.81M |
EPS (ttm) | -2.18 |
PE Ratio | n/a |
Forward PE | 14.21 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,906,002 |
Open | 19.00 |
Previous Close | 19.00 |
Day's Range | 19.00 - 19.00 |
52-Week Range | 8.82 - 21.86 |
Beta | 0.88 |
Analysts | Hold |
Price Target | 22.50 (+18.42%) |
Earnings Date | Nov 17, 2023 |
About ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and pr... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ICPT stock is "Hold." The 12-month stock price forecast is $22.5, which is an increase of 18.42% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/w/f/press12-2301014.jpg)
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commerci...
![](https://cdn.snapi.dev/images/v1/r/e/press20-2146962.jpg)
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisitio...
![](https://cdn.snapi.dev/images/v1/d/b/press14-2146103.jpg)
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed ...
![](https://cdn.snapi.dev/images/v1/a/v/press20-2122887.jpg)
Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Pending Acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with res...
![](https://cdn.snapi.dev/images/v1/f/n/press14-2105134.jpg)
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intercept Pharma...
![](https://cdn.snapi.dev/images/v1/d/l/press5-2098868.jpg)
Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences
BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation (“Purchaser”), has commenced a c...
![](https://cdn.snapi.dev/images/v1/5/9/press8-2080358.jpg)
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Ph...
![](https://cdn.snapi.dev/images/v1/h/w/press18-2078625.jpg)
Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma
MILWAUKEE , Sept. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.
![](https://cdn.snapi.dev/images/v1/u/a/press16-2078069.jpg)
ICPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intercept Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) to Alfasigma S.p.A. for $19.00 per share i...
![](https://cdn.snapi.dev/images/v1/f/v/biotech15-2077725.jpg)
Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium
Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that valu...
![](https://cdn.snapi.dev/images/v1/g/x/press12-2077672.jpg)
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICP...
![](https://cdn.snapi.dev/images/v1/m/e/press7-2000934.jpg)
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
MORRISTOWN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics t...
![](https://cdn.snapi.dev/images/v1/t/a/press18-1973407.jpg)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmac...
![](https://cdn.snapi.dev/images/v1/r/9/biotech20-1945480.jpg)
Intercept to reduce work force by one third as it aims for profitability
Intercept Pharmaceuticals Inc. ICPT, -1.62% on Friday said it will reduce its work force by one third as part of its plan to reach profitability in 2024. The layoffs will affect about 110 employees, b...
![](https://cdn.snapi.dev/images/v1/o/g/press6-1945467.jpg)
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company's focus on rare and serious liver diseases ...
![](https://cdn.snapi.dev/images/v1/z/g/press11-1945335.jpg)
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
Planned interim analysis from the first of two Phase 2 studies shows combination of OCA 5-10 mg + bezafibrate 400 mg normalized a range of biomarkers of PBC (ALP, total bilirubin, GGT, ALT and AST) in...
![](https://cdn.snapi.dev/images/v1/a/r/4axmylbc7nl7pbqtsiqfxoogva-1945178.jpg)
US FDA declines to approve Intercept's fatty liver disease drug
The U.S. Food and Drug Administration on Thursday declined to grant accelerated approval for Intercept Pharmaceuticals' drug to treat a type of fatty liver disease.
![](https://cdn.snapi.dev/images/v1/s/o/press17-1945159.jpg)
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics t...
![](https://cdn.snapi.dev/images/v1/z/a/press2-1943784.jpg)
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSIWRE / June 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmac...
![](https://cdn.snapi.dev/images/v1/f/d/press10-1939834.jpg)
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmac...
![](https://cdn.snapi.dev/images/v1/d/o/press6-1936712.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intercept Pharmaceuticals, Inc. - ICPT
NEW YORK , June 15, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT). Such investors a...
![](https://cdn.snapi.dev/images/v1/v/z/press2-1915379.jpg)
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmace...
![](https://cdn.snapi.dev/images/v1/n/j/press6-1910617.jpg)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmace...
![](https://cdn.snapi.dev/images/v1/o/q/image-3-1909394.jpg)
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/n/p/press12-1902468.jpg)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmace...